Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
KVHI$7.78+0.05(+0.65%)KVH Industries to Host Third Quarter Conference Call on November 5, 2026[9:22:13 AM ET]ARAI$0.11-0.01(-5.93%)Arrive AI to Report Q3 2026 Results and Host Webcast on November 13[9:19:00 AM ET]VIVK$1.82+0.32(+21.33%)Vivakor Announces Proposed Hydrogen Plant and Fueling Station at a Texas International Airport[9:15:00 AM ET]KBLB$0.080.00(0.00%)Why Kraig Labs’ Spider Silk Could Have a Future in Aerospace[9:15:00 AM ET]CWBK$41.000.00(0.00%)CW Bancorp Reports Third Quarter 2026 Financial Results CW Bancorp (OTCQX: CWBK), the parent company ("the Company") of CommerceWest Bank (the "Bank") reported consolidated net income for the third quarter ...[9:15:00 AM ET]NTHI$3.16+0.04(+1.25%)NeOnc’s Ambitious Brain Cancer Plans are Setting the Stage[9:10:00 AM ET]CURLF$8.59+0.11(+1.27%)Curaleaf Celebrates Graduation of Inaugural New York Incubator Program Class, Announces Future Cohorts and Multi-State Expansion Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf"), a leading international provider of consumer cannabis products, today announced the...[9:10:00 AM ET]PTHS$21.39+4.85(+29.32%)Pelthos Therapeutics to Combine with Castle Creek Biosciences, Creating Transformative Biotechnology Company Focused on Serious Diseases that Affect the Skin[9:09:49 AM ET]IDAI$2.95+0.09(+3.15%)Trust Stamp Appointed Exclusive Technology Partner for AFCAS, Ghana’s National Fire Safety Digitisation Programme[9:07:00 AM ET]XE$10.98-0.72(-6.13%)NRC Completes Landmark Safety Review of X-energy’s Xe-100 SMR[9:06:55 AM ET]AKTX$8.00-1.20(-13.04%)Akari Therapeutics to Highlight Novel RNA-Splicing ADC Payload Strategy at the 3rd Annual ADC Payload Summit[9:05:00 AM ET]SNDX$14.04-0.11(-0.78%)Syndax’s Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases[9:01:00 AM ET]GIGM$1.30+0.06(+5.28%)GigaMedia Announces Third-Quarter 2026 Financial Results GigaMedia Limited (NASDAQ: GIGM) today announced its third-quarter 2026 unaudited financial results. Comments from Management In the third quarter of ...[9:00:00 AM ET]

VOR · NASDAQ

Vor Biopharma Inc.

$20.60 -0.31 (-1.46%)

Company overview

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in Phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lack CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs' targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates, provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$1.1B
Employees
159
Headquarters
Cambridge, MA
Website
vorbio.com
CEO
Jean-Paul Kress
Listed
February 5, 2021
P/E
-0.03
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
-$28,000
Operating income
-$374M
EBITDA
-$1.1B
Net income
-$883M
EPS
-$575.83
Total assets
$507M
Total debt
$2.9M
Earnings yield
-2,879.15%

Price chart

12.0415.6719.2922.9126.54
VOR 1D NASDAQ O20.90H21.55L20.69C20.91+0.26 (+1.23%)Vol285.56K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
VORVor Biopharma Inc. Press release Vor Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update GlobeNewswire
VORVor Biopharma Inc. Stock news Vor Bio says its experimental drug slowed loss of kidney function in late-stage study Reuters
VORVor Biopharma Inc. Press release Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy GlobeNewswire
VORVor Biopharma Inc. Press release Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis GlobeNewswire
VORVor Biopharma Inc. Stock news Vor Biopharma Inc. (VOR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Seeking Alpha
VORVor Biopharma Inc. Press release Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis GlobeNewswire
VORVor Biopharma Inc. Press release Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
VORVor Biopharma Inc. Press release Vor Bio To Participate in Upcoming September Conferences GlobeNewsWire
VORVor Biopharma Inc. Stock news Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe News Wire
VORVor Biopharma Inc. Press release Vor Bio Appoints David Zaccardelli to Board of Directors GlobeNewsWire
VORVor Biopharma Inc. Stock news Vor Biopharma: A Financed Autoimmune Pivot With More Substance Than The Market Realizes Seeking Alpha
VORVor Biopharma Inc. Press release Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine GlobeNewsWire
VORVor Biopharma Inc. Press release Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update GlobeNewsWire
VORVor Biopharma Inc. Stock news Wall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to Trade Zacks Investment Research
VORVor Biopharma Inc. Press release Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewsWire
VORVor Biopharma Inc. Stock news Does Vor Biopharma (VOR) Have the Potential to Rally 117% as Wall Street Analysts Expect? Zacks Investment Research
VORVor Biopharma Inc. Stock news Vor Biopharma Inc. (NASDAQ:VOR) Short Interest Update Defense World
VORVor Biopharma Inc. Stock news Ra Capital Management, L.P. Sells 484,104 Shares of Vor Biopharma (NASDAQ:VOR) Stock Defense World
VORVor Biopharma Inc. Stock news Ra Capital Management, L.P. Sells 135,201 Shares of Vor Biopharma (NASDAQ:VOR) Stock Defense World
VORVor Biopharma Inc. Stock news Vor Biopharma: It's A Game Of Wait And See Seeking Alpha
See more
FAQ

Questions about Vor Biopharma Inc.

What does Vor Biopharma Inc. do?
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in Phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lack CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs' targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates, provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
What is VOR's market cap?
Vor Biopharma Inc. (VOR) is a listed stock with a live quote. The latest market cap on this page is $1.1B.
Where is Vor Biopharma Inc. headquartered?
Vor Biopharma Inc. is headquartered in Cambridge, MA.
How do I get VOR news from the API?
Call GET /v1/news?tickers=VOR. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does VOR news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for VOR, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the VOR price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs